Corvus Pharmaceuticals Inc. [NASDAQ: CRVS] gained 12.79% on the last trading session, reaching $7.67 price per share at the time. The company report on September 22, 2021 that Corvus Pharmaceuticals Provides Updates on Mupadolimab (Anti-CD73) Programs in Oncology and Infectious Disease.
Announces results published online in medRxiv in 40 patients from COVID-19 randomized controlled study, which showed primary and secondary endpoints trend toward more favorable outcome for mupadolimab treated patients vs. placebo.
COVID-19 study immune response data found to be consistent with proposed mechanism.
Corvus Pharmaceuticals Inc. represents 42.25 million in outstanding shares, while the company has a total market value of $336.33 million with the latest information. CRVS stock price has been found in the range of $6.81 to $8.11.
If compared to the average trading volume of 7.34M shares, CRVS reached a trading volume of 13258790 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Corvus Pharmaceuticals Inc. [CRVS]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for CRVS shares is $5.13 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on CRVS stock is a recommendation set at 2.20. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Cantor Fitzgerald have made an estimate for Corvus Pharmaceuticals Inc. shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on May 27, 2021. While these analysts kept the previous recommendation, Mizuho dropped their target price from $7 to $4. The new note on the price target was released on February 10, 2021, representing the official price target for Corvus Pharmaceuticals Inc. stock.
The Average True Range (ATR) for Corvus Pharmaceuticals Inc. is set at 0.90 The Price to Book ratio for the last quarter was 3.36, with the Price to Cash per share for the same quarter was set at 1.51.
Trading performance analysis for CRVS stock
Corvus Pharmaceuticals Inc. [CRVS] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 24.31. With this latest performance, CRVS shares gained by 248.64% in over the last four-week period, additionally plugging by 164.48% over the last 6 months – not to mention a rise of 91.27% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CRVS stock in for the last two-week period is set at 75.08, with the RSI for the last a single of trading hit 74.84, and the three-weeks RSI is set at 74.60 for Corvus Pharmaceuticals Inc. [CRVS]. The present Moving Average for the last 50 days of trading for this stock 2.87, while it was recorded at 7.50 for the last single week of trading, and 3.12 for the last 200 days.
Corvus Pharmaceuticals Inc. [CRVS]: A deeper dive into fundamental analysis
Return on Total Capital for CRVS is now -58.83, given the latest momentum, and Return on Invested Capital for the company is -8.17. Return on Equity for this stock declined to -8.37, with Return on Assets sitting at -7.09. When it comes to the capital structure of this company, Corvus Pharmaceuticals Inc. [CRVS] has a Total Debt to Total Equity ratio set at 3.20. Additionally, CRVS Total Debt to Total Capital is recorded at 3.10, with Total Debt to Total Assets ending up at 2.70. Long-Term Debt to Equity for the company is recorded at 1.71, with the Long-Term Debt to Total Capital now at 1.65.
Reflecting on the efficiency of the workforce at the company, Corvus Pharmaceuticals Inc. [CRVS] managed to generate an average of -$142,738 per employee.Corvus Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 5.60 and a Current Ratio set at 5.60.
An analysis of insider ownership at Corvus Pharmaceuticals Inc. [CRVS]
There are presently around $182 million, or 56.30% of CRVS stock, in the hands of institutional investors. The top three institutional holders of CRVS stocks are: ORBIMED ADVISORS LLC with ownership of 8,053,298, which is approximately 0% of the company’s market cap and around 0.10% of the total institutional ownership; BVF INC/IL, holding 3,678,626 shares of the stock with an approximate value of $28.21 million in CRVS stocks shares; and ECOR1 CAPITAL, LLC, currently with $27.45 million in CRVS stock with ownership of nearly New of the company’s market capitalization.
Positions in Corvus Pharmaceuticals Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 17 institutional holders increased their position in Corvus Pharmaceuticals Inc. [NASDAQ:CRVS] by around 4,460,187 shares. Additionally, 20 investors decreased positions by around 1,180,677 shares, while 17 investors held positions by with 18,071,288 shares. The mentioned changes placed institutional holdings at 23,712,152 shares, according to the latest SEC report filing. CRVS stock had 4 new institutional investments in for a total of 3,650,785 shares, while 3 institutional investors sold positions of 446,191 shares during the same period.